A Phase 2 interventional study of Efficacy of albendazole for early stage intervention of alveolar echinococcosis in Alveolar Echinococcosis, sponsored by Ministry of Health, Kyrgyzstan. Completed at 1 site in Kyrgyzstan. Open to participants aged 10 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Ministry of Health, Kyrgyzstan · Phase 2, Interventional, and Treatment
A new focus of subjects with lesions of alveolar echinococcosis caused by Echinococcus multilocularis has been found south of Gulcha in Osh province in Kyrgyzstan by an ultrasound surveillance. Prevalence of infections is approximately 6%. Most lesions are small. Current scientific evidence suggests that in the absence of treatment, alveolar echinococcosis has a case fatality rate approaching 100% within 10-15 years of infection. Albendazole is known to be effective as a parasitostatic treatment to prolong the life of subjects with this disease, possibly up to normal life expectancy with prolonged treatment. The trial will be a case control study to evaluate the treatment of subjects with early stage alveolar echinococcosis and the progression of disease.
No effect of albendazole - lesions progressing in all cases - indicating surgical treatment required in all cases.
Most lesions regressing in both the treatment and control group - indicates most early cases spontaneously resolve. Stop treatment but continue to monitor all cases.
25 studies on the registry are indexed under Echinococcosis; 4 are open to participants now.
Browse Echinococcosis studies →This is the only study on the registry with Ministry of Health, Kyrgyzstan as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cases defined as early stage alveolar echinococcosis receive daily dose of albendazole 2 x 400 mg
Drug: Efficacy of albendazole for early stage intervention of alveolar echinococcosis
Cases defined as early stage alveolar echinococcosis not receiving placebo treatment
Participants in the treatment arm will be treated with albendazole, 2 x 400 mg daily for the duration of the study. Treatment may be prolonged beyond the end of the study if clinically appropriate.
Progression of parasitic lesion
Increase in size of lesion or regression or calcification. Participants will be regularly assessed using ultrasound imaging of the lesion. The lesion size will me measured. The size of the lesion was measured using the cross-sectional image with the longest diameter on ultrasound. The measurement will be in millimeters.
Time frame: 3 years
Plan to share: No — IPD will be confidential or anonymised. Results will be published but no patient will be identifiable. Such will be freely available from mid 2019 and available between the trial investigators from the start of the trial
No publications or documents are linked to this record.
Ran from May 2017 to primary completion in Apr 2021, 47 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.